| . | PTFE group . | Homograft group . |
|---|---|---|
| N (%) | 104 (100) | 120 (100) |
| Median bypass time in min. (range) | 202 (152–461) | 203 (147–367) |
| Median XCT in min. (range) | 71 (45–178) | 72 (44–156) |
| Median circulatory arrest time in min. (range) | 3 (0–9) | 3 (0–21) |
| Source of pulmonary perfusion, n (%) | ||
| RV–PA conduit | 95 (91) | 118 (98) |
| mBTS | 5 (5) | 2 (2) |
| BDG | 4 (4) | 0 |
| Postoperative ECMO therapy, n (%) | 15 (14) | 24 (20) |
| Rethoracotomy for bleeding, n (%) | 4 (4) | 7 (6) |
| Median ICU stay in days (range) | 14 (2–55) | 15 (7–70) |
| Median hospital stay in days (range) | 26 (11–167) | 31 (17–121) |
| In-hospital mortality, n (%) | 13 (13) | 14 (12) |
| . | PTFE group . | Homograft group . |
|---|---|---|
| N (%) | 104 (100) | 120 (100) |
| Median bypass time in min. (range) | 202 (152–461) | 203 (147–367) |
| Median XCT in min. (range) | 71 (45–178) | 72 (44–156) |
| Median circulatory arrest time in min. (range) | 3 (0–9) | 3 (0–21) |
| Source of pulmonary perfusion, n (%) | ||
| RV–PA conduit | 95 (91) | 118 (98) |
| mBTS | 5 (5) | 2 (2) |
| BDG | 4 (4) | 0 |
| Postoperative ECMO therapy, n (%) | 15 (14) | 24 (20) |
| Rethoracotomy for bleeding, n (%) | 4 (4) | 7 (6) |
| Median ICU stay in days (range) | 14 (2–55) | 15 (7–70) |
| Median hospital stay in days (range) | 26 (11–167) | 31 (17–121) |
| In-hospital mortality, n (%) | 13 (13) | 14 (12) |
PTFE: polytetrafluorethylene; XCT: crossclamp time; mBTS: modified Blalock Taussig shunt; BDG: bidirectional Glenn operation; ICU: intensive care unit.
| . | PTFE group . | Homograft group . |
|---|---|---|
| N (%) | 104 (100) | 120 (100) |
| Median bypass time in min. (range) | 202 (152–461) | 203 (147–367) |
| Median XCT in min. (range) | 71 (45–178) | 72 (44–156) |
| Median circulatory arrest time in min. (range) | 3 (0–9) | 3 (0–21) |
| Source of pulmonary perfusion, n (%) | ||
| RV–PA conduit | 95 (91) | 118 (98) |
| mBTS | 5 (5) | 2 (2) |
| BDG | 4 (4) | 0 |
| Postoperative ECMO therapy, n (%) | 15 (14) | 24 (20) |
| Rethoracotomy for bleeding, n (%) | 4 (4) | 7 (6) |
| Median ICU stay in days (range) | 14 (2–55) | 15 (7–70) |
| Median hospital stay in days (range) | 26 (11–167) | 31 (17–121) |
| In-hospital mortality, n (%) | 13 (13) | 14 (12) |
| . | PTFE group . | Homograft group . |
|---|---|---|
| N (%) | 104 (100) | 120 (100) |
| Median bypass time in min. (range) | 202 (152–461) | 203 (147–367) |
| Median XCT in min. (range) | 71 (45–178) | 72 (44–156) |
| Median circulatory arrest time in min. (range) | 3 (0–9) | 3 (0–21) |
| Source of pulmonary perfusion, n (%) | ||
| RV–PA conduit | 95 (91) | 118 (98) |
| mBTS | 5 (5) | 2 (2) |
| BDG | 4 (4) | 0 |
| Postoperative ECMO therapy, n (%) | 15 (14) | 24 (20) |
| Rethoracotomy for bleeding, n (%) | 4 (4) | 7 (6) |
| Median ICU stay in days (range) | 14 (2–55) | 15 (7–70) |
| Median hospital stay in days (range) | 26 (11–167) | 31 (17–121) |
| In-hospital mortality, n (%) | 13 (13) | 14 (12) |
PTFE: polytetrafluorethylene; XCT: crossclamp time; mBTS: modified Blalock Taussig shunt; BDG: bidirectional Glenn operation; ICU: intensive care unit.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
